In navigating the multifaceted landscape of marijuana policy reform, the FDA’s exhaustive examination of cannabis, supplemented by insights from social media analysis, illuminates the intricate dynamics at play. Despite the agency’s recommendation for rescheduling, political pressures from congressional figures and stakeholders present hurdles towards a definitive decision.